US-based biopharmaceutical firm Baxalta has begun its Phase I clinical trial evaluating BAX 826, a recombinant Factor VIII (rFVIII) treatment for haemophilia A.

Using proprietary polysialic acid (PSA) technology, BAX 826 is the company’s second extended half-life treatment based on Advate, which is claimed to be the world’s most prescribed FVIII treatment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Advate is a full-length recombinant FVIII product that is processed without any blood-based additives, and which demonstrated efficacy and safety in treating haemophilia A,

Around 30 patients will be enrolled in three dosing groups in the open-label trial. Enrolment is expected to be completed by the end of the year.

"Baxalta is dedicated to advancing innovative research on the principle of direct factor replacement, a proven treatment model, to support as many patients as possible."

Baxalta Research & Development head and chief scientific officer John Orloff said: "This is an important step in evolving extended half-life treatments as we aim to improve bleed protection for hemophilia A patients while potentially offering once-weekly dosing.

"Baxalta is dedicated to advancing innovative research on the principle of direct factor replacement, a proven treatment model, to support as many patients as possible."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

BAX 826 is modified using PSA technology licensed from Xenetic Biosciences to extend its circulating half-life.

Baxalta has collaborated with Xenetic to develop new forms of polysialylated blood coagulation factors, including FVIII.

Xenetic’s PolyXen technology uses the biopolymer PSA to enhance the circulating half-life and pharmacokinetic profile of therapeutic proteins, peptides, and small molecules.

Preclinical trials have showed that BAX 826 offered an extended circulating half-life compared to standard rFVIII.

Baxalta’s haemophilia treatments include Adynovate, which was approved in the US for on-demand and prophylaxis treatment in adolescent and adult patients with hemophilia A, and is under regulatory review in Japan, Canada and Switzerland.